QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,036 signal articles · 514 in last 24h · 103,484 total before filter · latest 1h ago
514last 24h
2493last 7d
477● bullish (7d)
256● bearish (7d)
197publishers
AllMacro242Earnings1463M&A140Regulatory16Product4Analyst29
✕ clear all filtersticker: LLYSentiment:bullishneutralbearishshow all (incl. clickbait)
Omada Health Q1 Earnings Call Highlights
MarketBeat89d agoneutral
Omada Health Q1 Earnings Call Highlights

Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D

Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
Simply Wall St.90d agobullish
Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges

Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...

Schrodinger Q1 Earnings Call Highlights
MarketBeat91d agoneutral
Schrodinger Q1 Earnings Call Highlights

Schrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti

Eli Lilly and Company Q1 Earnings Call Highlights
MarketBeat95d agoneutral
Eli Lilly and Company Q1 Earnings Call Highlights

Eli Lilly and Company (NYSE:LLY) executives said the drugmaker started 2026 with “a strong start,” pointing to sharp first-quarter revenue growth, continued demand for its incretin medicines, a newly approved oral obesity therapy, and a slate of pipeline and business development milestones. Founday